Nevro Q4 EPS $(0.54) Misses $(0.49) Estimate, Sales $113.84M Beat $113.40M Estimate
Nevro (NYSE:NVRO) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.49) by 10.2 percent. This is a 37.21 percent increase over losses of $(0.86) per share from the same
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell
• RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022.
• Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.
Where Nevro Stands With Analysts
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Piper Sandler Maintains Underweight on Nevro, Lowers Price Target to $37
Piper Sandler analyst Adam Maeder maintains Nevro (NYSE:NVRO) with a Underweight and lowers the price target from $38 to $37.
Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023
Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…
Morgan Stanley Maintains Equal-Weight on Nevro, Lowers Price Target to $46
Morgan Stanley analyst Cecilia Furlong maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $49 to $46.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…